Back




Impact of pegylated interferon alfa-2b and
ribavirin on liver fibrosis in patients with chronic hepatitis C






*Please see editorial note at the end of this
article.

Download the entire published article in PDF

This study was initially reported at the AASLD
Conference in November 2001. This study found HCV therapy nonresponders and of
course responders to therapy can reverse fibrosis and other markers of disease
activity (necrosis and inflammation), are less likely to experience worsening
disease, and more likely to stabilize disease than patients who do not take
therapy. The authors found that patients with little or no fibrosis (early
disease) can experience a stopping in the progression rate per year whether or
not they were a responder or nonresponder. This suggests to me that it is worth
considering early therapy for HCV/HIV coinfected patients with genotype 1. Not
all patients experienced these benefits, but therapy is more likely to improve
progression for patients than no therapy. Nonresponders as well as sustained
responders to PegIFN+RBV experienced a slowing or reversal of the fibrosis
progression rate. Responders saw rate regress (improve) while nonresponders saw
progression stop. Age and body weight were associated with improvement in
fibrosis: patients who were younger when starting therapy were more likely to
see improvement, and patients with less body weight (<27 kg/m2) were also more
likely to see improved fibrosis.

Of particular note, the authors found that therapy
can reverse cirhhosis. 153 patients had cirrhosis at the time of the first
biopsy before treatment. The "reversal" of cirrhosis (change in fibrosis score
based on the biopsy sample) was observed in 75 patients (49 %), none in the
control regimen. Only one-third of patients in study had cirrhosis. so
nonresponders /relapsers appeared to benefit as well.

NATAP REPORT on AASLD presentation:
www.natap.org/2001/aasld2/day21.htm

The authors looked at 3000 patients who received 9
different regimens ranging from interferon monotherapy to pegylated
interferon+ribavirin. Overall 55% had improved activity progression
(inflammation & necrosis); 86% of sustained responders had improvement; 43% of
relapsers had improvement; and perhaps most interesting is that 36% of
nonresponders had improvement. Sustained responders were more likely to
stabilize their progression: 12% vs 36% for relapsers and 43% for nonresponders.

Only 2% of sustained responders experienced a
worsening, compared to 21% of the relapsers and 21% of the nonresponders.

Edit note: There appears to be a difference, based
on this data, between 48 weeks and 24 weeks treatment. Patients in this study
were more likely to improve activity but not necessarily fibrosis wih 48 weeks
rather than 24 weeks therapy. The interesting question is if 24 weeks for
genotype non-1 sustained responders produces the same improvement in activity &
fibrosis as 48 weeks therapy. The recent Pegasys/RBV data presented at EASL
(April 2002) reported non-1 genotypes had the same SVR with 24 or 48 weeks, but
the authors had not yet prepared the data on fibrosis and activity improvement.

Authors: Thierry Poynard, John McHutchison,
Michael Manns, Christian Trepo, Karen Lindsay, and others

Abstract:

Background & Aims of study: Liver fibrosis is an
important prognostic factor in patients with hepatitis C. The effect of
pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis
has not been established.

Methods: We pooled individual data from 3010 naive
patients with pretreatment and posttreatment biopsies from 4 randomized trials.
Ten different regimens combining standard interferon, PEG interferon, and
ribavirin were compared. The impact of each regimen was estimated by the
percentage of patients with at least 1 grade improvement in the necrosis and
inflammation (METAVIR score), the percentage of patients with at least 1 stage
worsening in fibrosis METAVIR score, and by the fibrosis progression rate per
year.

Results: Necrosis and inflammation improvement
ranged from 39% (interferon 24 weeks) to 73% (optimized PEG 1.5 and ribavirin; P
< 0.001). Fibrosis worsening ranges from 23% (interferon 24 weeks) to 8%
(optimized PEG 1.5 and ribavirin; P < 0.001). All regimens significantly reduced
the fibrosis progression rates in comparison to rates before treatment. The
reversal of cirrhosis was observed in 75 patients (49%) of 153 patients with
baseline cirrhosis. Six factors were independently associated with the absence
of significant fibrosis after treatment: baseline fibrosis stage (odds ratio
[OR] = 0.12; P < 0.0001), sustained viral response (OR = 0.36; P < 0.0001), age
< 40 years (OR = 0.51; P < 0.001), body mass index < 27 kg/m2 (OR = 0.65; P <
0.001), no or minimal baseline activity (OR = 0.70; P = 0.02), and viral load <
3.5 millions copies per milliliter (OR = 0.79; P = 0.03).

Conclusions: PEG-interferon and ribavirin
combination significantly reduces the rate of fibrosis progression in patients
with hepatitis C.

DISCUSSION BY AUTHORS

Approximately 170 million people worldwide are
infected with chronic hepatitis C virus (HCV).1 The degree of histologic
fibrosis is an important marker of the stage of the disease2 because the natural
history of hepatitis C involves the gradual progression of hepatic fibrosis that
can eventually lead to cirrhosis. Most of the complications related to chronic
infection occurs in patients who have established cirrhosis.3-5 Treatments that
could halt or diminish the progression of fibrosis would theoretically be
beneficial.

We have previously reported that the combination
regimen of interferon and ribavirin slows progression of liver fibrosis and even
leads to regression in a proportion of patients. The impact on fibrosis was
related both to the response to therapy and the duration of interferon
treatment.7 Recently, it has been shown that the pegylated form of interferon
(PEG-interferon) has a significantly higher efficacy in achieving sustained
response in comparison to standard interferon. This greater efficacy has been
observed both for monotherapy8-10 or in combination with ribavirin.11 The effect
of these new regimens on histological changes has not been well characterized.

The aim of this study was to compare the efficacy
of these different regimens (PEG-interferon alone or in combination with
ribavirin) on fibrosis progression and on the necrosis and inflammatory features
and to identify risk factors for these changes. This analysis was undertaken to
determine the impact of therapy in patients who eradicate the virus, and also in
patients who do not eradicate the virus during therapy.

Progression of fibrosis was analyzed by 3 methods

First, we compared the impact of the different
treatment regimens on the percentage of patients who improve by at least 1
fibrosis stage, remained stable, or worsened by at least 1 stage.

Secondly, we compared the different treatment
regimens according to the fibrosis progression rates per year before and after
treatment. These estimates have been extensively detailed and validated
previously.

The fibrosis progression rate after treatment was
defined as the ratio between the difference in fibrosis stage expressed in
METAVIR units between the 2 biopsies (before and after treatment) and the
interval between the 2 biopsies in years. The progression rate before treatment
was the ratio between the fibrosis stage in METAVIR units at the biopsy before
treatment and the estimated duration of infection in years. Because of the
nonnormal distribution of these estimates and the uncertainty of linearity, only
medians and nonparametric tests were used. In a previous study, we had validated
our estimate by comparison with paired biopsy estimates (our cohort and
meta-analysis of control groups).

Third, we assessed the impact of the different
treatment regimens adjusted by other risk factors in multivariate analyses. The
end point was the percentage of patients with significant fibrosis at the second
biopsy. Evolution of activity (necrosis and inflammation) was analyzed by
assessing for each regimen the percentage of patients who improve by at least
1-grade activity, remain stable, or worsen by at least 1 grade. We selected a
1-grade improvement in the necrosis and inflammation METAVIR scoring system as
its represent a major change. One grade in METAVIR is equivalent to 4 grades in
the Knodell index.14-15 This is twice the usual definition of histological
improvement.

Finally, we tested the hypothesis that the
reinforced regimens (9 regimens with interferon monotherapy pegylated or not for
48 weeks or combination with ribavirin) can reverse cirrhosis (change in
fibrosis score based on the biopsy sample) in comparison with the "control"
regimen (standard interferon alpha 2b 3 MU TIW 24 weeks which obtained only 5%
of sustained virological response). If there were more reversal versus the
control regimen this would strongly suggest an even more significant effect
versus an absence of treatment. For this purpose, we compared the percentage of
patients with baseline cirrhosis reversal between control and reinforced
regimens and control regimen. To take into account the sampling error we
compared the biopsy sizes between groups.

RESULTS

Of the 4493 naive patients enrolled in the 4
trials, 3010 had paired biopsies available with a 20-month mean duration between
the biopsies (Table 1 ). There were no statistically significant differences
between the original population and the population of patients with paired
biopsies included in this analysis. At baseline, 2243 patients had no
significant fibrosis (75%) and 767 significant fibrosis (25%), 673 (22%) had no
significant activity, and 2337 (78%) significant activity. The mean weight of
1880 patients in the United States was 84 kg vs. 74 kg for the 1330 patients not
in the United States (P < 0.0001).

The sustained response rate varied significantly
from 5% to 63% according to regimen:

5% for interferon 24 weeks (9 of 176), 16% for
interferon 48 weeks (86 of 540), 21% for PEG 0.5 (41 of 198), 27% for PEG 1.0
(48 of 178), 29% for PEG 1.5 (52 of 177), 34% for interferon-ribavirin 24 weeks
(131 of 383), 51% for interferon-ribavirin 48 weeks (334 of 658), 54% for 0.5
PEG-ribavirin (194 of 361), 56% for the low ribavirin dose and 1.5 PEG
combination (125 of 222), and 63% for the high ribavirin (more than 10.6 mg/kg)
and 1.5 PEG interferon combination (74 of 117).

Overall histologic response

Fibrosis stage was improved in 20% of patients,
stable in 65%, and worsened in 15%.

Impact of PEG interferon and ribavirin combination
regimen on activity progression between baseline and posttreatment biopsies:







(edit note: it appeared to me that the patients
received Peg Interferon + ribavirin for 48 weeks got the best results compared
to the other regimens).

Most of the differences were a 1 stage change: 16%
1 stage and 4% 2 or 3 stages for those biopsy pairs that improved; 12% 1 stage,
and 3% 2 or 3 stages for those that worsened. The activity grade improved in
55%, remained stable in 31%, and worsened in 14%. At the second biopsy,
cirrhosis was observed in 175 patients (6%) of 2834 patients treated with
reinforced regimens and in 18 of 176 patients treated with control regimen (10%;
P = 0.03). (edit. Note: Given more time for follow-up perhaps improvement will
increase).

Histologic response according to virologic
response

Among patients who achieved a virologic sustained
response, there was less frequently worsening of fibrosis (7%) in comparison
with relapsers (17%) or nonresponders (21%) (P < 0.001 for both comparisons;
Table 2 ), as well as more activity improvement (86% vs. 43% and 36%, P < 0.001
for both comparisons, respectively; Table 3 ). When relapsers were compared with
nonresponders, the differences were also significant (P = 0.046 and P = 0.009,
respectively).

Histologic response according to regimen

Between randomized different treatment arms there
was a significant difference in 2 separate trials for activity grade improvement
in favor of interferon-ribavirin 48 weeks in comparison with interferon alone 48
weeks or 24 weeks (Tables 2 and 3 ). There was no significant difference between
randomized arms for fibrosis.

Between regimens there were also highly
significant differences. Fibrosis worsening ranged from 8% in patients receiving
the PEG 1.5 and ribavirin high-dose combination to 23% in patients treated with
interferon for 24 weeks.

Activity improvement ranges from 73% in patients
receiving the PEG 1.5 and high-dose ribavirin combination to 39% in patients
treated by interferon 24 weeks.

Factors associated with the absence of significant
fibrosis at the end of follow-up in multivariate analysis

Six factors were independently associated with the
absence of significant fibrosis after treatment: baseline fibrosis stage,
sustained viral response, age younger than 40 years, body mass index lower than
27 kg/m2, no or mild baseline activity, and viral load lower than 3.5 millions
copies/mL (Table 5).

Treatment of patients with cirrhosis

A total of 153 patients had cirrhosis at the time
of the first biopsy before treatment. The "reversal" of cirrhosis (change in
fibrosis score based on the biopsy sample) was observed in 75 patients (49 %),
none in the control regimen.

One third of patients with cirrhosis reversal were
sustained responders; they were also younger and had significant improvement in
the activity grade in comparison to patients without cirrhosis reversal. The
size of the biopsies (at baseline or at the second biopsy) were not different
between patients with or without cirrhosis reversal. Among the 75 patients with
cirrhosis reversal, the second biopsy sample was graded stage 3 in 23 patients,
stage 2 in 26, stage 1 in 23, and no fibrosis in 3. The mean fibrosis score at
the second biopsy was 1.9 ± 0.9 (SD), and the mean activity grade improved from
2.5 ± 0.7 to 1.6 ± 0.9 (P < 0.01).

AUTHOR SUMMARY

This overview of 4 pivotal randomized trials has
permitted us to assess the incremental benefit of 10 different regimens on the
histological features of patients infected with hepatitis C virus. These
regimens given for 24 or 48 weeks allowed us to observe an improvement of
necrosis and inflammation grades and a reduction of fibrosis progression at
least during the 2 years' histological follow-up. This analysis has also
demonstrated that the histological improvement was related both to the viral
response and to several baseline factors.... half of the patients with baseline
cirrhosis treated with the reinforced regimen had a disappearance of cirrhosis
at the time of the subsequent follow-up biopsy.

Compared with our prior analyses, a new factor,
the body mass index, was strongly associated with fibrosis progression even
after adjustment for the 3 main factors previously identified, viral response,
fibrosis stage, and age.7 Gender was probably a confounding factor, which
disappears when body mass index was taken into account. Alcohol consumption was
not assessed during the treatment and follow-up periods in all of these trials.
This is a limitation of the present study. High alcohol consumption was an
exclusion criterion, but changes in alcohol consumption may have influenced
fibrosis progression...

the first approved regimen (interferon 3 MU TIW
for 24 weeks) had already an impact on the natural history of chronic hepatitis
C as demonstrated in meta-analysis of randomized trials21 and in historical or
randomized comparisons.2,6,22-23 Among 70 nontreated patients (when interferon
was not available) with 2 biopsies assessed retrospectively we observed an
improvement of activity in 17% and a worsening of fibrosis in 64% of
patients.2,6 In the present study, interferon monotherapy for 24 weeks was
associated with an improvement of activity grade in 37% and a worsening of
fibrosis stage in 24% of treated patients. Even if in a conservative approach
this first approved regimen was considered as the control regimen group, very
significant breakthroughs have been obtained thereafter. The last approved
regimen, the PEG-interferon and high-dose ribavirin combination, had the highest
histological benefit ever observed: an activity.

Before a generalized conclusion that cirrhosis can
be cured, several limitations of our study must be underlined.24 Cirrhosis
reversal was defined as a change in fibrosis score based on the biopsy sample. A
sampling error is possible especially between stage 3 (extensive fibrosis) and
stage 4 (cirrhosis), particularly with biopsies of small size. However, there
was no difference in biopsy sizes between patients with cirrhosis reversal and
those whose biopsies did not change. If we analyzed stage 3 and stage 4
together, there was also a very significant improvement rate in fibrosis in 50%
of cases (data not shown). One concordant fact is the association between
activity improvement and cirrhosis reversal: twice as many patients had none or
mild necroinflammatory features at the follow-up biopsy in comparison with
patients who still had cirrhosis. A sampling error cannot explain the
significant association between cirrhosis reversal and virologic response and
activity improvement. The patients with cirrhosis reversal were younger, and it
is possible that early cirrhosis is easier to reverse than more established
cirrhosis. These large prospective studies with repeated biopsies have finally
identified a new category of extensive fibrosis that could be named a
"reversible cirrhotic stage." Because the follow-up in these trials was less
than 48 weeks after the end of the treatment, the possibility of a continued
decrease in fibrosis among patients with a sustained virologic response should
be evaluated with long-term histologic and virologic follow-up studies. Recent
noninvasive biochemical markers of fibrosis may also be useful.

In virologic nonresponders, there was less
fibrosis regression and more fibrosis progression than in responders. However,
it may be incorrect to conclude that the combination regimen or interferons
alone are valueless in virologic nonresponders. By comparing the fibrosis
progression rate of virologic nonresponders after interferon to their estimated
progression before treatment and to nonrandomized matched untreated patients, we
and other investigators have previously observed6,7,23 that interferon slowed
the natural fibrosis progression observed before treatment (although the impact
was weaker than in sustained responders). This has been confirmed by a
randomized trial for necrosis and inflammation.23 In the present study, we also
observed a reduction of fibrosis progression rates in comparison to estimates
before treatment, especially among patients with initial significant fibrosis.
Because there is no certainty concerning the linearity of the fibrosis
progression, we used only medians and nonparametric methods for all comparisons.
It seems unfair not to take into account information based on 17 years of
disease evolution. The fibrosis stage at the first biopsy for each patient
represents an excellent abstract of this balance between extracellular matrix
formation and degradation. One weakness of the fibrosis progression rate
estimated during and after treatment is the short time elapsed between biopsies
with a mean of 20 months. This argues against the concept of stopping treatment
too early in patients without a sustained virologic response.26 The antifibrotic
and histologic efficacy of these regimens should be carefully considered before
prematurely stopping treatment, especially in patients who have significant
fibrosis. In a patient with a rapid fibrosis progression rate, it may be
clinically relevant to prevent fibrosis progression and cirrhosis complications
even if the virus is still detectable.27 The retrospective analyses of these
randomized trials suggested 2 options for maintenance therapy, either PEG-1.0
monotherapy which is the simplest and well-tolerated regimen or the combination
PEG-0.5-ribavirin, which was the most effective regimen in nonresponders on
necrosis and inflammation. These options should be validated prospectively.

This study permitted us to identify body mass
index as a major factor associated with significant fibrosis even in treated
patients. There are at least 2 factors explaining this association. First, the
viral efficacy of both interferon and ribavirin is related to a correct dosage
adjusted on the patient's weight.11 Secondly, there is a strong relationship
between fibrosis progression and metabolism. Recently, we observed that the
liver fibrosis risk was increased in overweight patients particularly when the
body mass index was greater than 27.28 Since the beginning of these pivotal
studies the mean weight is increasing particularly in patients in the United
States. The percentage of patients in the United States with a body mass index
greater than 27 was 43% in the first combination trial (1995), 51% in the second
(1997), and 57% in the last (1998). In a trial of patients not in the United
States, these percentages were 28%, 28%, and 32%, respectively.

We conclude that the combination of PEG
interferon-ribavirin has the potential to reduce the morbidity and mortality of
chronic hepatitis C by reducing fibrosis progression and the incidence of
cirrhosis. This effect was most prominent in patients who achieved a virologic
response, which is best achieved by the combination of PEG-interferon and
high-dose ribavirin. Independent of achieving a sustained viral response to
treatment, patients without extensive fibrosis at baseline, younger than 40
years of age, and with body mass index lower than 27 had a much lower
progression of liver fibrosis. Cirrhosis reversal seems possible in patients
with chronic hepatitis C.

Download the entire published article in PDF




--------------------------------------------------

EDITORIAL in Gastroenterology

Chronic hepatitis C virus (HCV) infection poses a
major worldwide health care problem as a leading cause of chronic liver disease
and cirrhosis. The burden of disease in the United States and in Europe is
substantial, and HCV infection is now the most common underlying diagnosis in
patients listed for liver transplantation. The liver disease is usually
insidious in onset and most of the morbidity and mortality occur as a direct
consequence of the development of liver fibrosis and cirrhosis and later
complications. In the majority of patients, a striking feature of this disease
is the relatively slow rate of progression of the liver fibrosis, with
significant problems usually developing after an interval of 15-20 years or
longer.

Fortunately, the last decade has witnessed major
improvements in our ability to treat this disease, with progressive improvements
in the rates of viral clearance accompanied by normalization of transaminases
and improvements in necro-inflammatory scores on liver histology. For some time,
a key question has been whether treatments that lead to viral clearance can
influence the rate of progression of liver fibrosis and perhaps in some cases
lead to regression of this complex pathologic process. The article in this issue
of GASTROENTEROLOGY by Poynard et al.1 analyzes the results of 4 previous major
clinical trials2-5 involving 3010 patients that were randomized to various
treatment regimes with either interferon or pegylated interferon, with or
without the addition of ribavirin (a total of 10 different regimens are
analyzed), and that had both pre- and post-treatment liver biopsies. This report
extends a previous similar study of 1509 chronic HCV patients6 but concentrates
more on the effects of antiviral treatment on patients with established
cirrhosis. The observations in the new study by Poynard et al. are very
important and provide clear evidence for major beneficial effects of antiviral
therapy on liver fibrosis; put simply, the more effective the treatment regime
in terms of clearance of HCV, the more likely there is to be a decrease in
severity of liver fibrosis. The most striking result was the finding that of a
total of 153 patients with cirrhosis, reversal was observed in 75 (49%).

Do I hear you say "But that's impossible,
cirrhosis isn't reversible!" If so, this paper and a summary of other studies in
the field may help to change your mind. There is now a substantial body of
evidence in both human liver disease and in animal models to indicate that liver
fibrosis and cirrhosis are dynamic processes that can both progress and regress
over time, depending in part on whether or not the underlying cause is
persistent.

But first, are we sure that the observations of
Poynard et al. are correct, or could there have been any confounding factors?
These could theoretically include the sampling error of liver biopsy, variable
pathological interpretation of the same liver biopsy (intraobserver variation),
or overenthusiastic interpretation of minor changes in liver fibrosis scores.
All of these problems were considered and addressed in the study. Sampling error
is a perennial problem, but is less likely to be relevant in a disease such as
HCV if liver biopsy specimens are of an adequate size. Table 1 in the report
indicates that liver biopsy size ranged from 14 to 16 mm in each of the
treatment regimes, which most pathologists would consider to be more than
adequate. One highly experienced pathologist, blinded to knowledge of the
treatment regime, using the METAVIR scoring system, assessed all liver biopsy
specimens. This methodology has been reported to yield a high degree of
reproducibility in the assessment of fibrosis.7 Moreover, the vast numbers of
patients under analysis would mean that errors caused by sampling or
inconsistent scoring of liver fibrosis are likely to be equally distributed
across groups. The numeric score obtained in the METAVIR system is a qualitative
and descriptive measure of a histologic appearance, not a quantitative assay of
the extent of liver fibrosis. The difference between grades must therefore be
interpreted accordingly. For example, grade 4 does not mean that there is twice
as much fibrosis as grade 2. The difference in the amount of hepatic collagen
between these 2 METAVIR grades would be manifold. This potentially leads to
problems with interpretation because a change of 1 grade at the top end of the
range (grade 4 to 3) could represent a far greater change in the quantity of
fibrotic matrix in the liver than at the lower grades (e.g., changing from grade
2 to 1).

The authors have addressed these difficulties by
looking at their data in a number of different ways to determine if the same
trends are observed with each approach. First, they have looked at the
proportion of patients in each treatment group that have improved, deteriorated,
or remained unchanged in the extent of liver fibrosis (see Figure 2 in the
article). For the regime with the worst sustained viral clearance rate (of 5% on
interferon only for 24 weeks), 12% of patients had an improved fibrosis score,
65% remained unchanged, and 23% deteriorated. In contrast, the results for
patients with the highest sustained viral clearance rates (of 63% on pegylated
interferon and high-dose ribavirin) were 24% improved, 68% unchanged, and 8%
with deterioration. Another method of examining the data was to compare the
calculated fibrosis progression rate before and after each treatment. This is
perhaps the most controversial aspect of the study because the fibrosis
progression rate before treatment is calculated by dividing the METAVIR fibrosis
score at the time of the initial biopsy by the estimated years of duration of
infection, whereas the post-treatment rate is calculated by looking at the
difference in the METAVIR score between the pre- and post-treatment liver
biopsies divided by the interval (in years). Both estimates assume linearity,
which may not be correct. In the analyzed studies, the median time between pre-
and post-treatment liver biopsies was only 20 months. Because many patients were
unchanged in their fibrosis score, the calculated post-treatment fibrosis
progression rate was 0 in a significant proportion. This highlights the
difficulty of comparing the pre- and post-treatment fibrosis progression rates.
Notwithstanding these concerns, the overall results (Table 4 in the report)
showed the same interesting trends, with a reduction in the rate of progression
of liver fibrosis after treatment of HCV and the greatest effect seen in
patients with sustained viral clearance. For patients with METAVIR fibrosis
stages 2, 3, and 4 at initial biopsy, the fibrosis progression rate before
treatment was 0.137 compared with -0.488 after treatment. In the same group of
patients, fibrosis progression rates after treatment were significantly lower in
patients that cleared HCV (-0.591) than in those with viral persistence (0.0).

The third method of analysis used by the authors
was to test the hypothesis that the reinforced regimes (all 9 regimes with
interferon monotherapy or not for 48 weeks or combination with ribavirin) can
reverse cirrhosis in comparison with the control regimen (of standard interferon
monotherapy for 24 weeks only). In the control group there were no cases of an
improvement in cirrhosis, which compared with 75 of 153 cases (49%) in the
reinforced regimes. Of those that had an improvement in cirrhosis, this was by 1
stage (to stage 3) in 23 patients, by 2 stages (to stage 2) in 26, by 3 stages
(to stage 1) in 23, and by a remarkable 4 stages (i.e., no remaining liver
fibrosis) in 3.

These are very important results because they show
that human liver fibrosis and cirrhosis can reverse to a very significant degree
histologically, particularly if there is treatment-induced clearance of HCV. The
implication is that this will be associated with improvements in long-term
clinical outcome in terms of morbidity and mortality, but such data are not yet
reported. There is a major need for the patients in the studies reported by
Poynard et al. to be followed for longer periods to determine if the
improvements in liver fibrosis continue to accrue, particularly in those that
have cleared HCV, and to determine if there are long-term beneficial effects on
clinical outcome. It would also be very interesting to know if there is an
associated measurable reduction in portal pressure in patients in whom there is
a documented improvement in liver fibrosis and cirrhosis, particularly in those
with documented cirrhosis and portal hypertension at the start of antiviral
therapy.

The suggestion that liver fibrosis and cirrhosis
are reversible is not a novel concept, but large-scale clinical trials in the
treatment of chronic hepatitis C are making this concept more widely known and
generally acceptable, thus helping to complete an important paradigm shift in
hepatology. Earlier reports of reversibility of liver fibrosis and cirrhosis
have tended to be smaller in scale but included a wide range of different liver
diseases. A common theme in all of these reports is an effective therapeutic
intervention that either removes or effectively suppresses the underlying
disease process. Reversibility of cirrhosis was reported over 30 years ago in
patients with hemochromatosis after long-term intensive venesection therapy.8
Improvements in liver fibrosis and cirrhosis have also been reported in patients
with autoimmune chronic active hepatitis9,10 and primary biliary cirrhosis11
after effective immunosuppressive therapy. There is also clear evidence of
reversibility of liver fibrosis in patients with chronic hepatitis B virus
infection after effective suppression of viral replication with lamivudine12 and
in chronic hepatitis D virus infection after treatment with long-term
interferon.13 More recently, reversibility of liver fibrosis and cirrhosis has
been reported in patients that have undergone surgical biliary decompression to
relieve chronic bile duct obstruction.14 The diversity of diseases and the
different nature of the interventions in these reports serve to indicate that we
are witnessing a generically applicable and important phenomenon in the liver's
response to injury and in its ability to undergo regeneration and repair. An
understanding of the cell and molecular mechanisms involved in the process of
reversibility of liver fibrosis are therefore of major importance and may point
the way forward to new therapeutic strategies that attempt to mimic or promote
this process.

Liver fibrosis is characterized by proliferation
and activation of hepatic stellate cells (HSCs), which develop a myofibroblastic
phenotype and are the main cellular source of the fibrillar collagens and other
matrix proteins that accumulate in chronic liver disease.15 The fate of these
cells and the mechanisms by which fibrotic matrix is removed have been studied
in animal models of reversibility of liver fibrosis.16-18 These studies have
shown that activated HSCs rapidly undergo apoptosis after 4 weeks of CCl4 liver
injury, if the stimulus is withdrawn. Apoptosis of activated HSCs was also
observed after decompressive surgery in the bile duct ligation model of liver
injury. In the regression phase, fibrotic liver matrix is degraded and removed
as a consequence of the action of metalloproteinases, including MMP-1, MMP-2,
and MMP-14, and this occurs in part because of a rapid decrease in expression of
metalloproteinase inhibitors, such as TIMP-1. There is significant interplay
between these various events because TIMP-1 has recently been shown to be
antiapoptotic for activated HSCs, an effect that was mediated via the MMP
inhibitory effects of this molecule.19 Apoptosis of activated HSCs is also
decreased in mice that are transgenic for mutated collagen I that is resistant
to the effects of MMPs.20 These studies indicate that the key events in the
regression of liver fibrosis are interlinked and include apoptosis of HSCs,
decreased expression of TIMP-1, increased MMP activity, increased degradation of
collagen I, and altered HSC-matrix interactions. These events combine to further
promote apoptosis of activated HSCs. As yet, it is not known which of these
events is the primary regulatory factor, but these observations have opened up
the prospect of novel therapeutic strategies for the treatment of liver fibrosis
by trying to initiate regression via these pathways.

It is likely that this sequence of cell and
molecular events is operative during reversal of liver fibrosis and cirrhosis
after treatment for HCV, but as yet there are very few studies of such
mechanisms in human disease. There are data consistent with this suggestion in
patients with chronic HBV infection treated with lamivudine.12 Serial biopsies
performed in these patients demonstrated that expression of smooth muscle actin
(an indirect measure of the number of activated HSCs) was decreased as liver
fibrosis improved after lamivudine treatment.

Many key questions remain with regard to the
reversibility of human liver fibrosis and cirrhosis. For example, can disease
regress to the extent that the liver returns to complete normality? The Poynard
et al. report suggests that this occurred in 3 patients who had established
cirrhosis on their first biopsy. Experimental animal evidence suggests that some
fibrosis may persist for very long periods after withdrawal of liver injury,
particularly if the remaining collagen is cross-linked (Iredale JP, personal
communication, October 2001) and thus more resistant to the action of
metalloproteinases. Against this background, it is interesting that Poynard et
al. found that cirrhosis was more likely to reverse in younger patients, which
led them to suggest that early cirrhosis may reverse more readily than
established disease. A knowledge of the way in which cirrhosis can change during
regression may also be important because there is evidence to suggest that
cirrhosis changes from a micronodular to a macronodular type as it regresses.21
Clearly, the macronodular phase of regressing cirrhosis in a patient with HCV
could be difficult to diagnose on a single repeat liver biopsy. The case for
complete resolution of cirrhosis is therefore not yet made conclusively in human
liver disease, but the study of Poynard et al. challenges all of us to accept
that the traditional view of cirrhosis as a progressive irreversible disease is
no longer correct. This augurs well for the future of our patients with chronic
HCV infection, particularly if they clear the virus with treatment. This study
also encourages further scientific investigation of the key cell and molecular
mechanisms of liver fibrosis and raises the prospect that an antifibrotic agent
aimed at promoting regression of disease may be an important therapeutic
strategy for the future.

Author: Professor Michael Arthur is a consultant
to Glaxo-Smith-Kline and to Cambridge Antibody Technology.

















[Non-text portions of this message have been removed]